News

For the fourth quarter of 2010, the net income attributable to Pfizer was $2.89bn, compared to $767m for the same period in 2009. For the full year ended

For the fourth quarter of 2010, the company has generated net income of $271.75m, compared to $306m for the same period in 2009. However, the income from operations

This has led the net income rise to 67.4bn yen ($823m) in the period ended 31 December 2010 from 53.9bn yen a year earlier. This has also translated

The Versus EVM provides users access to patient, staff and equipment locations on mobile devices as it is synced to the Versus Advantages Real-time Locating System (RTLS). This

iPierian has assigned the iPSC patent estate it previously acquired from Bayer Schering Pharma in 2008 to Kyoto University. In turn, Kyoto University and iPS Academia Japan have

The randomised, double-blind, placebo-controlled Phase I Study evaluated the safety, tolerability and pharmacokinetic profile of NRM8499, compared to tramiprosate in 67 young and elderly healthy subjects. The study

The randomized, double-blind, placebo-controlled Phase III trial will evaluate the safety and efficacy of GALNS in patients with MPS IVA. In the study, patients will receive doses of

CURNA is engaged in the discovery of new drugs for the treatment of illnesses such as cancer, heart disease, metabolic disorders and genetic anomalies. Its broad platform technology

PharmaSmart’s latest kiosk offers Internet connectivity, patient data tracking, and patient health record integration. Its connectivity network has already collected and stored four million patient readings, including blood